Abstract: PURPOSE: Cumulating evidence indicates that germline variants in the Wnt, Notch, and Hedgehog pathways are involved in colon carcinoma progression and metastasis. We investigated germline polymorphisms in a comprehensive panel of Wnt, Notch, and Hedgehog pathway genes to predict time to recurrence (TTR) and overall survival in patients with stage II and III colon carcinoma. EXPERIMEN-TAL DESIGN: A total of 742 consecutively collected patients with stage II and III colon carcinoma were included in this retrospective study. Genomic DNA was analyzed for 18 germline polymorphisms in Wnt, Notch, and Hedgehog pathway genes (SFRP, DKK 2 and 3, AXIN2, APC, MYC, TCF7L2, NOTCH2, and GLI1) by TaqMan 5'-exonuclease assays. RESULTS: In univariate analysis, the homozygous mutant variant of GLI1 rs2228226 G>C was significantly associated with decreased TTR in a recessive genetic model after adjustment for multiple testing [HR = 2.35; confidence interval (95% CI), 1.48-3.74; P < 0.001] and remained significant in multivariate analysis including clinical stage, lymphovascular-, vascular-, and perineural-invasion (HR = 2.43; CI 95%, 1.52-3.87; P < 0.001). In subanalyses, the association was limited to patients with surgery alone (HR = 3.21; CI 95%, 1.59-6.49; P = 0.001), in contrast with patients with adjuvant chemotherapy (HR = 0.82; CI 95%, 0.35-1.95; P = 0.657). When the subgroup of patients with "high-risk" GLI1 rs2228226 C/C genotype was analyzed, no benefit of adjuvant 5-fluorouracil-based chemotherapy could be found. CONCLUSION: This is the first study identifying GLI1 rs2228226 G>C as an independent prognostic marker in patients with stage II and III colon carcinoma. Prospective studies are warranted to validate our findings. 
Translational relevance
Germline variants in cancer stem cells (CSCs) may have an important role in tumor recurrence despite adjuvant chemotherapy. In the present study, we investigated germline polymorphisms in a comprehensive panel of genes in the Wnt, Notch and Hedgehog pathways that have been previously investigated for their biological function and/ or associated with CSCs and cancer risk or clinical outcome to predict tumor recurrence in patients with stage II and III colon carcinoma. These common DNA-sequence variations may alter the gene function and/ or activity including transcription, translation or splicing, thereby causing inter-individual differences in relation to tumor recurrence capacity. Our study provides the first evidence that GLI1 rs2228226 G>C may predict early tumor recurrence in stage II and III colon carcinoma patients.
Introduction
Colorectal carcinoma is the third cause of cancer-related death in the United States and the second cause of cancer mortality in Europe (1, 2) . Across all stages, approximately 30% of patients with colon carcinoma develop synchronous or metachronous metastases (3). The 5-year survival rate of colon carcinoma patients with metastatic disease is less than 10% (4).
In the absence of adjuvant chemotherapy, approximately 50% of colon carcinoma patients with resectable disease are cured by surgery alone, whereas 50% relapse. Using adjuvant chemotherapy following surgery rescues approximately 15% of patients from the relapsing group. In current practice, the majority of these colon carcinoma patients receive adjuvant treatment unnecessarily, either because they were cured by surgery alone or because they will relapse despite adjuvant treatment. It is therefore essential to identify patients who will benefit from adjuvant therapy, sparing others needless toxicity and the financial burden of chemotherapy that will not work (5-7). Tumor recurrence after curative surgery remains a major obstacle for improving overall cancer survival, which may be in part due to the existence of cancer stem cells (CSC). Current therapies target populations of rapidly growing and differentiated tumor cells, but have shown to lack activity against CSCs (8, 9) . CSCs therefore may have an important role in tumor recurrence despite adjuvant chemotherapy (9, 10) . There is strong evidence that the embryonic signaling pathways Wnt, Notch and Hedgehog operate in CSCs and drive tumor progression, metastasis and chemoresistance (11) (12) (13) (14) (15) (16) (17) (18) .
There is substantial germline genetic variability within the genes of the Wnt, Notch and Hedgehog pathways, including multiple single nucleotide polymorphisms (SNPs common DNA-sequence variations may alter the gene function and/ or activity including transcription, translation or splicing, thereby causing inter-individual differences in relation to tumor recurrence capacity and chemoresistance (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) . Furthermore, common gene variants may also predict chemoresistance and toxicity to 5-FU and/ or oxaliplatin as recently shown for the thymidylate synthetase (Ts), 5 methyltetrahydrofolate-homocysteine methyltransferase reductase (MTRR), multidrug resistance protein 2 (MRP2), dihydropyrimidine dehydrogenase (DPD) and the X-ray repair cross-complementing protein 1 (XRCC1) genes (30) (31) (32) (33) (34) (35) .
In the present study, we investigated 18 germline polymorphisms in a comprehensive panel of genes in the Wnt, Notch and Hedgehog pathways that have been previously investigated for their biological function and/ or associated with cancer risk or clinical outcome to predict tumor recurrence in patients with stage II and III colon carcinoma. This study was conducted adhering to the reporting recommendations for prognostic tumor marker studies (36, 37) .
Research. 
Candidate gene polymorphisms
Common and putatively functional Wnt, Notch and Hedgehog gene polymorphisms were selected using stringent and pre-defined selection criteria: (a) minor allele frequency ≥10% in Caucasians (based on the population genetics section in the Ensembl Genome Browser); (b) polymorphism that could alter the function of the gene in a biologically relevant manner (either published data or predicted function using Functional-Single-Nucleotide- 
Isolation of genomic DNA and determination of single nucleotide polymorphisms
Genomic DNA was extracted from paraffin-embedded normal tissue adjacent to the tumor samples to obtain germline DNA. DNA isolation was performed by use of the QIAamp DNA mini Kit (Qiagen) and according to the manufacturer's instructions. Genotypes were centrally determined by 5'-exonuclease assay (TaqMan) at the Medical University of Graz. Primer and probe sets were designed and manufactured using Applied Biosystems 'Assay-by-Design' custom service (Applera, Austria). General TaqMan reaction conditions were according to the manufacturer of the assays. As a control for consistency of genotyping methods, determination of genotypes was repeated in at least 96 samples. The rules of good laboratory and clinical practice were observed. The investigator analyzing the germline polymorphisms was blinded to the clinical dataset.
Immunohistochemistry
Immunohistochemistry was performed on a Ventana XT immunostainer using UltraView DAB as the detection kit and CC1 32min as heat induced epitope retrieval (HIER). 
Statistical analysis
The endpoint of the study was time to recurrence (TTR). TTR was calculated from the date of 
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The true mode of inheritance of all polymorphisms tested has not been established yet and we evaluated a codominant, dominant or recessive genetic model where appropriate. The significance threshold for an overall type I error rate of 0.05 was set at p<0.003 based on a conservative Bonferroni correction for multiple comparison. The interactions between polymorphisms and adjuvant chemotherapy on TTR were tested by comparing likelihood ratio statistics between the baseline and nested Cox proportional hazards models that include the multiplicative product term. Case-wise deletion for missing polymorphisms was used in univariate and multivariate analyses. The association between the GLI1 rs2228226 genotypes and GLI1, IL17 and IL21 expression in tumor was examined using chi-square test.
All analyses have been performed using the SPSS 21.0 statistical software package (SPSS Inc., Sunnyvale, USA).
Results
The baseline characteristics of the 742 patients included in this analysis are summarized in Genotyping was successful in at least 91% of patients for each polymorphism analyzed, with the exception of DKK3 rs7396187 (86.8%). In failed cases, genotyping was not successful because of limited quantity and/ or quality of extracted genomic DNA. The genotype frequencies for all polymorphisms were within the probability limits of Hardy-Weinberg equilibrium.
In our study cohort, we found a significant association between tumor size, lymph node involvement, lymphovascular-, vascular-and perineural-invasion and clinical stage with TTR and OS. Additionally, tumor location and histopathological grade were significantly associated with OS (Table 2) . When the polymorphisms were correlated with the clinicopathological features, we found a significant association between APC rs454886 G>A and tumor size (p=0.001) and vascular invasion (p=0.001), observing larger tumors and increased vascular invasion in patients carrying the wildtype. Furthermore, colon cancer patients with NOTCH2 rs11249433 T>C wildtype showed significantly increased lymphovascular invasion (p=0.001). No association was found between the other tested polymorphisms and clinicopathological features (data not shown).
The associations between all polymorphisms tested and TTR and OS are provided in Table 3. GLI1 rs2228226 G>C, AXIN2 rs3923086 T>G and AXIN2 rs4791171 A>G showed an association with TTR in a codominant model (p<0.05; Table 3 ). In multiple testing, only GLI1 rs2228226 G>C using a recessive genetic model remained significant for TTR in univariate analysis (HR 2.35, Cl95% 1.48-3.74, p<0.001). Patients harbouring the homozygous mutant variant (C/C) had a median TTR of 52.2 months, in contrast to patients carrying the G/G or G/C genotype with a median TTR of 121.8 months (Figure 1) . In OS analyses, no statistically significant association between the polymorphisms and OS could be found (Table 3 In interaction analysis, there was a significant association between GLI1 rs2228226 G>C and adjuvant chemotherapy with TTR (p<0.05). When only patients with surgery alone were analyzed, we found a highly significant association between GLI1 rs2228226 G>C and TTR When we correlated the GLI1 rs2228226 genotypes using the recessive genetic model with GLI1, IL17 and IL21 expression in tumor in a subset of patients (n=27 for wildtype and heterozygous mutant and n=12 for homozygous mutant) we found no significant association (p=0.697, p=0.338, p=0.596, respectively). 
Discussion
It is becoming increasingly apparent that disease progression and chemoresistance are driven by a multitude of signaling networks and the analysis of a single marker may fail to predict clinical outcome and treatment efficacy with a high degree of accuracy and reproducibility. Therefore, it is critical to adopt and implement a pathway-based approach.
In the present study, we investigated germline polymorphisms in a comprehensive panel of Wnt, Notch and Hedgehog pathway genes to predict tumor recurrence in patients with stage II and III colon carcinoma. Our results indicate that GLI1 rs2228226 G>C may be an independent prognostic marker. Our findings further suggest that patients harbouring the homozygous mutant variant do not benefit from adjuvant 5-FU-based chemotherapy.
The exact molecular mechanisms involved in how the GLI1 rs2228226 G>C polymorphism exerts effect on colon carcinoma outcome are not clarified yet. Non-synonymous polymorphisms result in amino acid changes and thus may affect the protein function (40) .
We used the F-SNP database to predict the functional effects of the analyzed polymorphisms. F-SNP gathers computationally predicted functional information about polymorphisms, particularly aiming to facilitate identification of disease-related polymorphisms in association studies (38, 39) . When used for GLI1 rs2228226 G>C, F-SNP predicted changes in splicing regulation and post-translation, thus supporting the effects seen in our study. In a recent study, however, Paez et al investigated the association of GLI1 rs2228226 with TTR in 234 patients with stage III and high-risk stage II patients, all treated with adjuvant 5-FU-based chemotherapy, but found no clinical effect (41) . Moreover, in genome-wide association studies GLI1 rs2228226 has not been identified as a prognostic or predictive marker in colorectal cancer (42) (43) (44) . 
GLI1 rs2228226 G>C develop severe intestinal inflammation, indicating that tolerance to inflammatory stimuli requires a fully functional Hedgehog signal transduction network (51).
The most highly expressed cytokine in mice harbouring the mutant allele of GLI1 rs2228226 G>C in their study was IL-23, a molecule that promotes the differentiation of T-helper IL-17-producing (TH17) cells that are involved in inflammation processes, including inflammatory bowel disease (57) . IL-23 is also known as a pro-carcinogenic cytokine, which is mainly In our study cohort, we found a statistically significant association between GLI1 rs2228226 
17 are more likely to develop a recurrent disease, due to a supportive inflammatory microenvironment for tumor growth. However, we could not experimentally underline this biological function since the GLI1 rs2228226 genotypes were not significantly associated with GLI1, IL17 and IL21 expression in tumor in a subset of our patient cohort. Our results further suggest that patients harbouring the homozygous mutant variant of GLI1 rs2228226 G>C do not benefit from adjuvant 5-FU-based chemotherapy. We also found a significant association between APC rs454886 G/G and larger tumor size and increased vascular invasion, furthermore, patients with NOTCH2 rs11249433 TT showed an increased lymphovascular invasion. F-SNP predicted changes in the transcriptional regulation for the intronic APC rs454886 G>A. No prediction could be provided for the intergenic located NOTCH2 rs11249433 T>C by the software (38, 39) . Since the biological function of these SNPs is unknown, these associations remain to be elucidated.
The strength of the present study is the large sample size and the long follow-up period.
However, because of the retrospective study design a selection bias cannot be fully excluded. The subgroup of "high-risk" GLI1 rs2228226 C/C included overall only 40 patients and only 21 patients treated with various chemotherapy regimens. Therefore, it is currently unknown if this association is truly significant and/ or if only patients with monotherapy or both, mono-and combination therapy do not benefit in this "high-risk" subgroup. Another limitation is the lack of the MSI-status in our study cohort, hence the evaluation of GLI1 rs2228226 G>C in comparison to MSI was not feasible. Finally, the method of preservation of the tissue samples was performed by 3 different institutions over a number of years, undermining the consistency of sample preparation. 
